PL3252069T3 - (11beta, 17beta)-17-hydroksy-11-[4-(metylosulfonylo)fenylo]-17-(pentalofuorometylo)estra-4,9- dien-3-on do leczenia chorób - Google Patents

(11beta, 17beta)-17-hydroksy-11-[4-(metylosulfonylo)fenylo]-17-(pentalofuorometylo)estra-4,9- dien-3-on do leczenia chorób

Info

Publication number: PL3252069T3
Authority: PL; Poland
Prior art keywords: beta; pentalfuoromethyl; estra; dien; methylsulfonyl
Prior art date: 2009-07-20

Application number

PL17176264T

Other languages

English (en)

Inventor

Wolfgang Schwede

Ulrich Klar

Carsten Möller

Andrea Rotgeri

Wilhelm Bone

Original Assignee

Bayer Pharma Aktiengesellschaft

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-07-20

Filing date

2010-07-07

Publication date

2019-09-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43383964&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3252069(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-07-07 Application filed by Bayer Pharma Aktiengesellschaft filed Critical Bayer Pharma Aktiengesellschaft

2019-09-30 Publication of PL3252069T3 publication Critical patent/PL3252069T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/36—Antigestagens
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
- C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Epidemiology (AREA)
Gynecology & Obstetrics (AREA)
Diabetes (AREA)
Pregnancy & Childbirth (AREA)
Steroid Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PL17176264T 2009-07-20 2010-07-07 (11beta, 17beta)-17-hydroksy-11-[4-(metylosulfonylo)fenylo]-17-(pentalofuorometylo)estra-4,9- dien-3-on do leczenia chorób PL3252069T3 (pl)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
DE102009034362A DE102009034362A1 (de)	2009-07-20	2009-07-20	17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
PCT/EP2010/004149 WO2011009531A2 (de)	2009-07-20	2010-07-07	17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-derivate, verfahren zu ihrer herstellung und ihre verwendung zur behandlung von krankheiten
EP12194455.7A EP2623510B1 (de)	2009-07-20	2010-07-07	17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-derivate, verfahren zu ihrer herstellung und ihre verwendung zur behandlung von krankheiten
EP10735198A EP2432798B1 (de)	2009-07-20	2010-07-07	17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-derivat, verfahren zu seine herstellung und seine verwendung zur behandlung von krankheiten
EP17176264.4A EP3252069B1 (de)	2009-07-20	2010-07-07	(11.beta.,17.beta.)-17-hydroxy-11-[4-(methylsulfonyl)phenyl]-17-(pentalfuoromethyl)estra-4,9-dien-3-one zur behandlung von krankheiten

Publications (1)

Publication Number	Publication Date
PL3252069T3 true PL3252069T3 (pl)	2019-09-30

Family

ID=43383964

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
PL12194455T PL2623510T3 (pl)	2009-07-20	2010-07-07	Pochodne 17-hydroksy-17-pentafluoroetylo-estra-4,9(10)-dieno-11-arylu, sposób ich wytwarzania i ich zastosowanie w leczeniu chorób
PL17176264T PL3252069T3 (pl)	2009-07-20	2010-07-07	(11beta, 17beta)-17-hydroksy-11-[4-(metylosulfonylo)fenylo]-17-(pentalofuorometylo)estra-4,9- dien-3-on do leczenia chorób
PL10735198T PL2432798T3 (pl)	2009-07-20	2010-07-07	Pochodna 17-hydroksy-17-pentafluoroetylo-estra-4,9(10)-dieno-11-arylu, sposób jej wytwarzania i jej zastosowanie w leczeniu chorób

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL12194455T PL2623510T3 (pl)	2009-07-20	2010-07-07	Pochodne 17-hydroksy-17-pentafluoroetylo-estra-4,9(10)-dieno-11-arylu, sposób ich wytwarzania i ich zastosowanie w leczeniu chorób

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL10735198T PL2432798T3 (pl)	2009-07-20	2010-07-07	Pochodna 17-hydroksy-17-pentafluoroetylo-estra-4,9(10)-dieno-11-arylu, sposób jej wytwarzania i jej zastosowanie w leczeniu chorób

Country Status (48)

Country	Link
US (4)	US20120149670A1 (pl)
EP (4)	EP3252069B1 (pl)
JP (3)	JP5795312B2 (pl)
KR (2)	KR101854059B1 (pl)
CN (1)	CN102482317B (pl)
AR (1)	AR077491A1 (pl)
AU (1)	AU2010275849B2 (pl)
BR (1)	BR112012001344B8 (pl)
CA (1)	CA2768407C (pl)
CL (1)	CL2012000166A1 (pl)
CO (1)	CO6491067A2 (pl)
CR (2)	CR20170091A (pl)
CU (1)	CU20120012A7 (pl)
CY (3)	CY1114260T1 (pl)
DE (1)	DE102009034362A1 (pl)
DK (3)	DK2623510T3 (pl)
DO (2)	DOP2012000015A (pl)
EA (2)	EA021946B1 (pl)
EC (2)	ECSP12011616A (pl)
ES (3)	ES2730209T3 (pl)
GT (1)	GT201200012A (pl)
HK (1)	HK1171456A1 (pl)
HN (1)	HN2012000137A (pl)
HR (3)	HRP20130558T1 (pl)
HU (2)	HUE043757T2 (pl)
IL (1)	IL216967B (pl)
IN (1)	IN2012DN00598A (pl)
JO (2)	JO3009B1 (pl)
LT (2)	LT2623510T (pl)
MA (1)	MA33445B1 (pl)
ME (2)	ME01534B (pl)
MX (2)	MX2012000930A (pl)
MY (1)	MY179447A (pl)
NO (1)	NO2623510T3 (pl)
NZ (2)	NZ597639A (pl)
PE (2)	PE20121085A1 (pl)
PL (3)	PL2623510T3 (pl)
PT (3)	PT2432798E (pl)
RS (1)	RS52811B (pl)
SG (3)	SG10201811830PA (pl)
SI (3)	SI2432798T1 (pl)
TN (1)	TN2012000028A1 (pl)
TR (1)	TR201908600T4 (pl)
TW (1)	TWI505830B (pl)
UA (1)	UA106502C2 (pl)
UY (1)	UY32791A (pl)
WO (1)	WO2011009531A2 (pl)
ZA (1)	ZA201201222B (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE102009034368A1 (de)	2009-07-20	2011-01-27	Bayer Schering Pharma Aktiengesellschaft	17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034367A1 (de)	2009-07-20	2011-01-27	Bayer Schering Pharma Aktiengesellschaft	17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034362A1 (de) *	2009-07-20	2011-01-27	Bayer Schering Pharma Aktiengesellschaft	17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034366A1 (de)	2009-07-20	2011-01-27	Bayer Schering Pharma Aktiengesellschaft	17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de)	2009-07-21	2011-02-10	Bayer Schering Pharma Aktiengesellschaft	17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034525A1 (de)	2009-07-21	2011-01-27	Bayer Schering Pharma Aktiengesellschaft	17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102010007722A1 (de)	2010-02-10	2011-08-11	Bayer Schering Pharma Aktiengesellschaft, 13353	Progesteronrezeptorantagonisten
DE102010007719A1 (de)	2010-02-10	2011-08-11	Bayer Schering Pharma Aktiengesellschaft, 13353	Progesteronrezeptorantagonisten
DE102011088270A1 (de)	2011-12-12	2013-06-13	Bayer Intellectual Property Gmbh	(11ß ,17ß)-17-hydroxy-11-[4-(methylsulfonyl)phenyl]-17-(pentafluorethyl)estra-4,9-dien-3-on zur Behandlung von Morbus Charcot Marie Toot
PL2983671T3 (pl) *	2013-04-11	2019-04-30	Bayer Pharma AG	Postać dawkowania antagonisty receptora progesteronowego
US9096641B2 (en)	2013-06-05	2015-08-04	Evestra, Inc.	Imidazolyl progesterone antagonists
MA42103A (fr) *	2015-05-18	2018-03-28	Bayer Pharma AG	Régime posologique à base de modulateur sélectif du récepteur de la progestérone (rpm)
EP3214092A1 (en)	2016-03-04	2017-09-06	Bayer Pharma Aktiengesellschaft	Prodrugs of the selective progesterone receptor modulator (sprm) (11.beta.,17.beta.)-17-hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one
EP3384913A1 (en)	2017-04-03	2018-10-10	Bayer Pharma Aktiengesellschaft	Selective progesterone receptor modulators and stabilized estrogen level in patient
JP2021500359A (ja) *	2017-10-26	2021-01-07	クリスタルファーマシューティカル（スーチョウ）カンパニー，リミテッド	選択的プロゲステロンの受容体モジュレーターの結晶形およびその製造方法
AU2023227418A1 (en)	2022-03-01	2024-08-29	Altin Biosciences Corporation	Crila® and egcg compositions for treatment of fibroids

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA8231B (en)	1981-01-09	1982-11-24	Roussel Uclaf	New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
DE3347126A1 (de) *	1983-12-22	1985-07-11	Schering AG, 1000 Berlin und 4709 Bergkamen	11ss-aryl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
FR2596395B1 (fr) *	1986-03-26	1989-05-26	Roussel Uclaf	Nouveaux steroides comportant un cycle spirannique en position 17, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
US5272140A (en)	1987-01-23	1993-12-21	Akzo N.V.	11-aryl steroid derivatives
FR2620707B1 (fr)	1987-09-18	1989-12-08	Roussel Uclaf	Nouveaux steroides comportant un cycle spirannique a 3, 4 ou 6 chainons en position 17, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
US4954490A (en)	1988-06-23	1990-09-04	Research Triangle Institute	11 β-substituted progesterone analogs
FR2644789B1 (fr)	1989-03-22	1995-02-03	Roussel Uclaf	Nouveaux steroides 19-nor, 3-ceto comportant une chaine en 17 aminosubstituee, leur procede de preparation et les intermediaires de ce procede, leur application comme medicaments et les compositions pharmaceutiques les contenant
JP3202224B2 (ja)	1989-08-04	2001-08-27	シエーリングアクチエンゲゼルシヤフト	１１β―アリール―ゴナ―４，９―ジエン―３―オン、その製造方法及びそれを含有する調剤学的調製剤
US5407928A (en)	1990-08-15	1995-04-18	Schering Aktiengesellschaft	11β-aryl-gona-4,9-dien-3-ones
CA2100514C (en) *	1992-07-29	2005-03-29	Johannes A. M. Hamersma	17-spiromethylene steroids
FR2718354B1 (fr)	1994-04-08	1996-05-03	Roussel Uclaf	Application des composés antiglucocorticoïde pour la préparation de médicaments destinés à la prévention ou au traitement des manifestations liées au syndrome de sevrage des narcotiques et les compositions les renfermant.
DE4426601A1 (de)	1994-07-27	1996-02-01	Schering Ag	Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri
PT792152E (pt)	1994-11-22	2004-07-30	Balance Pharmaceuticals Inc	Metodos de contracepcao
JP4260886B2 (ja)	1996-05-01	2009-04-30	アメリカ合衆国	新規の抗プロゲステロンとしての２１―置換プロゲステロン誘導体
WO1998005679A2 (en)	1996-08-05	1998-02-12	Duke University	Mixed agonists of the progesterone receptor and assays therefor
DE19635525A1 (de)	1996-08-20	1998-02-26	Schering Ag	7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
FR2757400B1 (fr)	1996-12-19	1999-12-17	Hoechst Marion Roussel Inc	Application des composes antiglucocorticoides dans le traitement des psychoses ou des comportements addictifs
DE19706061A1 (de)	1997-02-07	1998-08-13	Schering Ag	Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
US20010016578A1 (en)	1997-06-18	2001-08-23	Balance Pharmaceuticals, Inc.	Compositions and methods for contraception and for treatment of benign gynecological disorders
JPH11171774A (ja)	1997-12-05	1999-06-29	Kyowa Hakko Kogyo Co Ltd	血球増多剤
AR015500A1 (es)	1997-12-23	2001-05-02	Schering Ag	11 BETA-HALoGENO-ESTRATRIENOS SUSTITUIDOS EN 7 ALFA, PROCEDIMIENTO PARA ELABORAR PREPARADOS FARMACEUTICOS QUE CONTIENEN TALES 11 BETA-HALOGENO-ESTRATRIENOSSUSTITUIDOS EN 7 ALFA, ASI COMO SU UTILIZACION EN LA ELABORACION DE MEDICAMENTOS.
US6020328A (en)	1998-03-06	2000-02-01	Research Triangle Institute	20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
AU3344099A (en)	1998-04-17	1999-11-08	Kyowa Hakko Kogyo Co. Ltd.	Analgetic agent
US6172052B1 (en) *	1998-12-04	2001-01-09	Research Triangle Institute	17β-acyl-17α-propynyl-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US6476079B1 (en)	1999-12-23	2002-11-05	Leiras Oy	Devices for the delivery of drugs having antiprogestinic properties
EP1157996A1 (de)	2000-05-23	2001-11-28	JENAPHARM GmbH	Neue Festkörperformen des Mesoprogestins 11Beta-[4E-(Hydroxyiminomethyl)-phenyl]-17Alpha-methoxymethyl-17Beta-methoxy-estra-4,9-dien-3-on
WO2002022646A2 (en)	2000-09-18	2002-03-21	Applied Research Systems Ars Holding N.V.	Method for the preparation of 21-hydroxy-6,19-oxidoprogesterone (21oh-6op)
DE10051609A1 (de)	2000-10-18	2002-05-02	Schering Ag	Hemmung der Wachstumsfaktorabhängigkeit von Tumorzellen
AU2002215958B2 (en)	2000-10-18	2006-08-17	Schering Ag	Use of inhibitors of progesterone receptor for treating cancer
DE60115274T2 (de)	2000-10-18	2006-07-27	Schering Ag	Verwendung von antiprogestinen zur prophylaxe und behandlung von hormonabhängigen erkrankungen
DK1365765T3 (da) *	2001-01-09	2007-10-29	Bayer Schering Pharma Ag	Anvendelse af antigestagener til inhibition af accelereret endometrial modning under infertilitetsbehandling
US20020143000A1 (en) *	2001-01-09	2002-10-03	Christa Hegele-Hartung	Use of antigestagens for inhibiting accelerated endometrial maturation during infertility treatment
DE10159217A1 (de)	2001-11-27	2003-06-05	Schering Ag	17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate
ES2252670T3 (es)	2002-05-03	2006-05-16	Schering Ag	Esteroides con fluoroalquilo en 17a y benzaldoxima en 11beta, procedimiento para su preparacion, formulaciones farmaceuticas que contienen estos esteroides, asi como su utilizacion para la produccion de medicamentos.
DE10221034A1 (de)	2002-05-03	2003-11-20	Schering Ag	17alpha-Fluoralkyl-11ß-benzaldoxim-Steroide, Verfahren zu deren Herstellung, diese Steroide enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
EP1768625B1 (en)	2004-07-09	2011-02-09	The Population Council, Inc.	Sustained release compositions containing progesterone receptor modulators
WO2006101009A1 (ja)	2005-03-18	2006-09-28	Hirose Engineering Co., Ltd.	ナイルレッド系赤色発光化合物、及び発光素子
US20070105828A1 (en)	2005-08-19	2007-05-10	Glenmark Pharmaceuticals Limited	Novel polymorph form M of mifepristone and process for its preparation
EP1862468A1 (de)	2006-06-02	2007-12-05	Bayer Schering Pharma Aktiengesellschaft	Kristallines 11beta-(4-Acetylphenyl)-20,20,21,21,21-pentafluor-17-hydroxy-19-nor-17alpha-pregna-4,9-dien-3-on
DE102006054535A1 (de)	2006-11-15	2008-05-21	Bayer Schering Pharma Aktiengesellschaft	Progesteronrezeptorantagonisten
US20090075989A1 (en) *	2006-12-21	2009-03-19	Wolfgang Schwede	Non-steroidal progesterone receptor modulators
EP1986845A1 (en)	2007-03-01	2008-11-05	PRS Mediterranean Ltd.	Uv resistant multilayered cellular confinement system
EP2123279A1 (de)	2008-05-14	2009-11-25	Bayer Schering Pharma Aktiengesellschaft	Sequentielle Verabreichung von 20,20,21,21,21-Pentafluor-17-hydroxy-1 1beta-[4-(hydroxyacetyl) phenyl]-19-nor-17alpha-pregna-4,9-dien-3-on und einem oder mehreren Gestagenen zur Behandlung gynäkologischer Erkrankungen
DE102009034362A1 (de)	2009-07-20	2011-01-27	Bayer Schering Pharma Aktiengesellschaft	17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten

2009
- 2009-07-20 DE DE102009034362A patent/DE102009034362A1/de not_active Withdrawn
2010
- 2010-07-07 DK DK12194455.7T patent/DK2623510T3/en active
- 2010-07-07 PE PE2012000076A patent/PE20121085A1/es active IP Right Grant
- 2010-07-07 SI SI201030255T patent/SI2432798T1/sl unknown
- 2010-07-07 EP EP17176264.4A patent/EP3252069B1/de active Active
- 2010-07-07 KR KR1020167020690A patent/KR101854059B1/ko active IP Right Grant
- 2010-07-07 DK DK17176264.4T patent/DK3252069T3/da active
- 2010-07-07 PT PT107351983T patent/PT2432798E/pt unknown
- 2010-07-07 ME MEP-2013-69A patent/ME01534B/me unknown
- 2010-07-07 KR KR1020127001509A patent/KR101687853B1/ko active IP Right Grant
- 2010-07-07 MY MYPI2012000105A patent/MY179447A/en unknown
- 2010-07-07 PE PE2016002208A patent/PE20170084A1/es unknown
- 2010-07-07 EP EP10735198A patent/EP2432798B1/de active Active
- 2010-07-07 EA EA201200121A patent/EA021946B1/ru not_active IP Right Cessation
- 2010-07-07 SG SG10201811830PA patent/SG10201811830PA/en unknown
- 2010-07-07 CN CN201080032941.3A patent/CN102482317B/zh not_active Expired - Fee Related
- 2010-07-07 SG SG10201404159VA patent/SG10201404159VA/en unknown
- 2010-07-07 MA MA34552A patent/MA33445B1/fr unknown
- 2010-07-07 PT PT121944557T patent/PT2623510T/pt unknown
- 2010-07-07 NZ NZ597639A patent/NZ597639A/en not_active IP Right Cessation
- 2010-07-07 ME MEP-2019-131A patent/ME03400B/me unknown
- 2010-07-07 WO PCT/EP2010/004149 patent/WO2011009531A2/de active Application Filing
- 2010-07-07 EP EP12194455.7A patent/EP2623510B1/de active Active
- 2010-07-07 LT LTEP12194455.7T patent/LT2623510T/lt unknown
- 2010-07-07 ES ES17176264T patent/ES2730209T3/es active Active
- 2010-07-07 TR TR2019/08600T patent/TR201908600T4/tr unknown
- 2010-07-07 DK DK10735198.3T patent/DK2432798T3/da active
- 2010-07-07 AU AU2010275849A patent/AU2010275849B2/en not_active Ceased
- 2010-07-07 EA EA201301263A patent/EA025150B1/ru not_active IP Right Cessation
- 2010-07-07 LT LTEP17176264.4T patent/LT3252069T/lt unknown
- 2010-07-07 ES ES12194455.7T patent/ES2648292T3/es active Active
- 2010-07-07 BR BR112012001344A patent/BR112012001344B8/pt not_active IP Right Cessation
- 2010-07-07 SI SI201031890T patent/SI3252069T1/sl unknown
- 2010-07-07 PL PL12194455T patent/PL2623510T3/pl unknown
- 2010-07-07 RS RS20130259A patent/RS52811B/en unknown
- 2010-07-07 SG SG2012000725A patent/SG177519A1/en unknown
- 2010-07-07 JP JP2012520921A patent/JP5795312B2/ja not_active Expired - Fee Related
- 2010-07-07 NZ NZ623417A patent/NZ623417A/en not_active IP Right Cessation
- 2010-07-07 PT PT17176264T patent/PT3252069T/pt unknown
- 2010-07-07 PL PL17176264T patent/PL3252069T3/pl unknown
- 2010-07-07 CR CR20170091A patent/CR20170091A/es unknown
- 2010-07-07 SI SI201031582T patent/SI2623510T1/sl unknown
- 2010-07-07 US US13/376,512 patent/US20120149670A1/en not_active Abandoned
- 2010-07-07 EP EP17176265.1A patent/EP3272763A1/de not_active Withdrawn
- 2010-07-07 ES ES10735198T patent/ES2416461T3/es active Active
- 2010-07-07 HU HUE17176264A patent/HUE043757T2/hu unknown
- 2010-07-07 CA CA2768407A patent/CA2768407C/en active Active
- 2010-07-07 HU HUE12194455A patent/HUE037339T2/hu unknown
- 2010-07-07 NO NO12194455A patent/NO2623510T3/no unknown
- 2010-07-07 IN IN598DEN2012 patent/IN2012DN00598A/en unknown
- 2010-07-07 PL PL10735198T patent/PL2432798T3/pl unknown
- 2010-07-07 MX MX2012000930A patent/MX2012000930A/es active IP Right Grant
- 2010-07-07 UA UAA201201277A patent/UA106502C2/uk unknown
- 2010-07-09 TW TW099122758A patent/TWI505830B/zh not_active IP Right Cessation
- 2010-07-16 UY UY0001032791A patent/UY32791A/es not_active Application Discontinuation
- 2010-07-18 JO JOP/2010/0255A patent/JO3009B1/ar active
- 2010-07-20 AR ARP100102636A patent/AR077491A1/es active IP Right Grant
2011
- 2011-12-13 US US13/324,912 patent/US8278469B2/en not_active Expired - Fee Related
- 2011-12-14 IL IL216967A patent/IL216967B/en active IP Right Grant
2012
- 2012-01-19 TN TNP2012000028A patent/TN2012000028A1/en unknown
- 2012-01-20 CL CL2012000166A patent/CL2012000166A1/es unknown
- 2012-01-20 GT GT201200012A patent/GT201200012A/es unknown
- 2012-01-20 CR CR20120040A patent/CR20120040A/es unknown
- 2012-01-20 CU CU2012000012A patent/CU20120012A7/es active IP Right Grant
- 2012-01-20 CO CO12008148A patent/CO6491067A2/es active IP Right Grant
- 2012-01-20 HN HN2012000137A patent/HN2012000137A/es unknown
- 2012-01-20 EC EC2012011616A patent/ECSP12011616A/es unknown
- 2012-01-20 DO DO2012000015A patent/DOP2012000015A/es unknown
- 2012-01-20 MX MX2013006080A patent/MX338217B/es unknown
- 2012-02-17 ZA ZA2012/01222A patent/ZA201201222B/en unknown
- 2012-11-30 HK HK12112380.9A patent/HK1171456A1/xx not_active IP Right Cessation
2013
- 2013-06-18 HR HRP20130558AT patent/HRP20130558T1/hr unknown
- 2013-06-26 CY CY20131100516T patent/CY1114260T1/el unknown
2015
- 2015-05-27 JP JP2015107399A patent/JP2015178522A/ja not_active Withdrawn
- 2015-06-04 US US14/731,232 patent/US9717739B2/en active Active
- 2015-11-12 DO DO2015000276A patent/DOP2015000276A/es unknown
2016
- 2016-03-28 JO JOP/2016/0059A patent/JO3732B1/ar active
2017
- 2017-02-06 JP JP2017019347A patent/JP6130087B1/ja not_active Expired - Fee Related
- 2017-04-04 US US15/478,803 patent/US10155004B2/en active Active
- 2017-11-21 HR HRP20171805TT patent/HRP20171805T1/hr unknown
- 2017-11-23 CY CY20171101228T patent/CY1119661T1/el unknown
2018
- 2018-06-22 EC ECSENADI201847708A patent/ECSP18047708A/es unknown
2019
- 2019-06-12 HR HRP20191049TT patent/HRP20191049T1/hr unknown
- 2019-06-12 CY CY20191100611T patent/CY1121926T1/el unknown

Also Published As

Publication number	Publication date
HUE037339T2 (hu)	2018-08-28
PL2432798T3 (pl)	2013-08-30
CY1121926T1 (el)	2020-10-14
KR20120046182A (ko)	2012-05-09
LT2623510T (lt)	2017-12-11
CA2768407C (en)	2017-10-24
PE20170084A1 (es)	2017-03-30
EP2623510B1 (de)	2017-08-23
JO3732B1 (ar)	2021-01-31
MX2012000930A (es)	2012-03-26
ES2416461T3 (es)	2013-08-01
US20120149670A1 (en)	2012-06-14
JP6130087B1 (ja)	2017-05-17
ME01534B (me)	2014-04-20
MY179447A (en)	2020-11-06
US20150342962A1 (en)	2015-12-03
PT2432798E (pt)	2013-06-28
UA106502C2 (uk)	2014-09-10
ME03400B (me)	2020-01-20
DK3252069T3 (da)	2019-06-24
DOP2012000015A (es)	2016-04-15
SI3252069T1 (sl)	2019-06-28
US20120094969A1 (en)	2012-04-19
HRP20191049T1 (hr)	2019-09-20
AU2010275849A1 (en)	2012-02-02
MA33445B1 (fr)	2012-07-03
AU2010275849B2 (en)	2014-12-18
ECSP18047708A (es)	2018-06-30
US10155004B2 (en)	2018-12-18
KR101687853B1 (ko)	2016-12-19
GT201200012A (es)	2013-10-15
HRP20171805T1 (hr)	2017-12-29
US8278469B2 (en)	2012-10-02
CO6491067A2 (es)	2012-07-31
PT2623510T (pt)	2017-11-24
CR20120040A (es)	2012-03-12
TW201105331A (en)	2011-02-16
TR201908600T4 (tr)	2019-07-22
SG177519A1 (en)	2012-02-28
BR112012001344B8 (pt)	2021-05-25
EA201200121A1 (ru)	2012-07-30
TWI505830B (zh)	2015-11-01
KR20160093110A (ko)	2016-08-05
HUE043757T2 (hu)	2019-09-30
US9717739B2 (en)	2017-08-01
LT3252069T (lt)	2019-06-10
CU20120012A7 (es)	2012-07-31
EA201301263A1 (ru)	2014-08-29
EA025150B1 (ru)	2016-11-30
DOP2015000276A (es)	2018-04-15
IL216967A0 (en)	2012-02-29
CR20170091A (es)	2018-02-06
DK2432798T3 (da)	2013-07-01
EP2432798B1 (de)	2013-04-03
NZ623417A (en)	2015-10-30
MX338217B (es)	2016-04-07
PT3252069T (pt)	2019-06-18
WO2011009531A3 (de)	2011-04-28
JP2015178522A (ja)	2015-10-08
CA2768407A1 (en)	2011-01-27
CY1119661T1 (el)	2018-04-04
EP3252069B1 (de)	2019-04-03
NO2623510T3 (pl)	2018-01-20
SI2623510T1 (sl)	2017-12-29
DE102009034362A1 (de)	2011-01-27
HN2012000137A (es)	2015-05-04
JO3009B1 (ar)	2016-09-05
CN102482317A (zh)	2012-05-30
KR101854059B1 (ko)	2018-05-02
HK1171456A1 (en)	2013-03-28
EA021946B1 (ru)	2015-10-30
EP3272763A1 (de)	2018-01-24
TN2012000028A1 (en)	2013-09-19
JP5795312B2 (ja)	2015-10-14
BR112012001344A2 (pt)	2016-03-15
CL2012000166A1 (es)	2012-08-31
SG10201811830PA (en)	2019-02-27
PE20121085A1 (es)	2012-08-04
CY1114260T1 (el)	2016-08-31
ES2648292T3 (es)	2017-12-29
BR112012001344B1 (pt)	2020-09-24
ZA201201222B (en)	2022-11-30
HRP20130558T1 (hr)	2013-07-31
NZ597639A (en)	2014-04-30
AR077491A1 (es)	2011-08-31
US20170202857A1 (en)	2017-07-20
IN2012DN00598A (pl)	2015-06-12
RS52811B (en)	2013-10-31
CU24080B1 (pl)	2015-03-30
SI2432798T1 (sl)	2013-08-30
JP2012533575A (ja)	2012-12-27
EP2623510A1 (de)	2013-08-07
WO2011009531A2 (de)	2011-01-27
EP2432798A2 (de)	2012-03-28
DK2623510T3 (en)	2017-12-04
UY32791A (es)	2011-02-28
PL2623510T3 (pl)	2018-02-28
CN102482317B (zh)	2014-09-17
SG10201404159VA (en)	2014-10-30
ECSP12011616A (es)	2012-02-29
IL216967B (en)	2018-06-28
EP3252069A1 (de)	2017-12-06
JP2017105813A (ja)	2017-06-15
ES2730209T3 (es)	2019-11-08

Publication	Publication Date	Title
LT3252069T (lt)	2019-06-10	(11.beta.,17.beta.)-17-hidroksi-11-[4-(metilsulfonil)fenil]-17-(pentalfuormetil)estra-4,9-dien-3-onas, skirtas naudoti ligų gydymui
PL2205273T3 (pl)	2017-09-29	Zastosowanie zmodyfikowanych komórek w leczeniu stwardnienia rozsianego
HK1220631A1 (zh)	2017-05-12	用於遞送治療劑的陰離子核心組合物以及製備和使用所述組合物的方法
IL225198A (en)	2016-02-29	Aminotetrahydropyrenic Compounds, Pharmaceutical Preparations Containing Them and Their Use in the Treatment of Diabetes
IL205742A (en)	2014-12-31	4 - (4-Cyano-2-Theoaryl) dihydropyrimidinones, their preparation processes, medications containing them and their use
CL2007002640A1 (es)	2008-06-20	Compuestos derivados de 3-(6-oxo-1,6-dihidro-piridin-3-il)-benzamida; composicion farmaceutica; y uso en el tratamiento del cancer.
CL2007002642A1 (es)	2008-07-18	Compuestos derivados de 3-(6-oxo-1,6-dihidro-piridin-3-il)-benzamida; composicion farmaceutica; y uso en el tratamiento del cancer.
AP2490A (en)	2012-10-04	Therapeutic compositions and the use thereof
HK1166983A1 (zh)	2012-11-16	包含用於治療疾病或紊亂的化合物的固體形式，其組合物，及其用途
IL211400A0 (en)	2011-05-31	Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof
IL213168A0 (en)	2011-07-31	1,2,4-oxadiazole derivatives and their therapeutic use
LT2315773T (lt)	2016-11-10	Polipeptidai, polinukleotidai ir kompozicijos, skirti naudoti latentinės tuberkuliozės gydymui
SI2739615T1 (sl)	2017-07-31	Fenil-3-aza-biciklo(3.1.0)heks-3-il-metanoni in njihova uporaba kot zdravilo
ZA201005905B (en)	2011-11-30	Methods,dosage forms,and kits for administering ziprasidone without food
IT1391866B1 (it)	2012-01-27	Composizione iniettabile di polinucleotidi per il trattamento di patologie osteoarticolari.
IL206277A0 (en)	2010-12-30	1,2,4-oxadiazole compounds for the treatment of autoimmune diseases
GB0710778D0 (en)	2007-07-18	Disposable humidifier for use with tobacco products
PL1945243T3 (pl)	2015-12-31	Zastosowanie kalcytoniny w leczeniu rzs
IL215840A (en)	2015-06-30	Arylsulfonamide compounds are converted into two positions 2 and 5, their pharmaceutical composition containing them and their use in the treatment of ccr3-related diseases
EP2279179A4 (en)	2011-12-07	PHENYL-PIPERAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AND USE THEREOF
GB2458868B (en)	2011-04-06	Fluphenazine based combination for use in the treatment of protein aggregation diseases
ZA201005306B (en)	2011-04-28	5-o-substituted 3-n-phenyl-1,3,4-oxadiazolones for medical use
EP2192122A4 (en)	2011-05-11	DITHIOLOPYRROLON COMPOUNDS, THEIR PREPARATION AND THEIR USE
HK1164862A1 (en)	2012-09-28	3-benzofuranyl-indol-2-one derivatives substituted at the 3 position, preparation thereof, and therapeutic use thereof
IL186286A0 (en)	2008-01-20	Use of calcitonin as combined treatment therapy for the management of inflammatory disease conditions